The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Transforming CDMO partnerships through
a holistic understanding of quality
This whitepaper explores how a holistic approach to quality strengthens CDMO partnerships and drives better outcomes across pharmaceutical development and manufacturing.
Quality is the underpinning of success in the pharmaceutical development and manufacturing industry.
A commitment to quality is not only required to meet regulatory guidelines — it is also foundational to:
- Accelerating time to market
- Reducing unnecessary risk
- Improving return on investment
- Creating effective medicines
- Ultimately saving patient lives
Despite its critical importance, quality is often mischaracterized, whether by conflating it with compliance, describing it as an end-of-the-line activity, or attributing responsibility to a single team.
In fact, quality is difficult to fully classify because it’s not defined by one single activity, role, process, strategy, or outcome. Rather, it’s a combination and culmination of all these factors — plus more.
This whitepaper takes an in-depth look at key indicators of CDMO quality, identifying tools and best practices to drive continuous improvement, strengthen collaboration, and ultimately cultivate trust.
Download the full whitepaper to explore the key indicators of CDMO quality and partnership performance in detail.
